What were Medtronic’s (NYSE:MDT) Q4 2026 revenue results?

Medtronic reported fourth-quarter revenue of $9.8 billion, a 9.9% increase year-over-year. On an organic basis, revenue grew 6.6%, excluding currency translation and divestiture effects.

How did Medtronic (NYSE:MDT) perform on earnings per share in Q4 2026?

Non-GAAP diluted earnings per share reached $1.55 for the quarter, reflecting steady operational performance across the company’s therapeutic portfolios.

What were Medtronic’s full-year 2026 revenue and growth metrics?

Total revenue for fiscal 2026 was $36.4 billion, up 8.4% year-over-year, with a 5.8% organic increase, indicating broad-based adoption of Medtronic’s medical technologies.

How did full-year GAAP earnings per share perform?

GAAP EPS increased 3.3% year-over-year to $3.73, demonstrating consistent profitability growth alongside revenue expansion.

How strong is Medtronic’s (NYSE:MDT) cash generation?

Medtronic generated $7.3 billion in cash from operations and $5.4 billion in free cash flow for fiscal 2026, providing robust liquidity to support operations and shareholder returns.

Image for illustrative purposes only. Not a real photo.

Medtronic caps fiscal year with revenue surge and 49th dividend increase

Written by Isaac FrancisPublished Jun. 3 2026Last Updated Jun. 3 2026

Medtronic (NYSE:MDT) reported a 9.9% increase in fourth-quarter revenue to $9.8 billion, closing out its fiscal year 2026 with broad-based operational momentum across its core therapeutic portfolios.

On an organic basis, which excludes the impacts of foreign currency translations and business divestitures, revenue grew 6.6% for the three-month period, reflecting healthy healthcare consumer utilization and steady adoption of the company's advanced surgical technologies.

Non-GAAP diluted earnings per share for the quarter arrived at $1.55.

For the full fiscal year 2026, total revenue reached $36.4 billion, marking an 8.4% reported increase and a 5.8% organic gain compared to the previous fiscal year.

Medtronic reported full-year GAAP earnings per share of $3.73, up 3.3% year over year.

Financial liquidity remained an operational anchor, with the Dublin-based medical technology giant generating $7.3 billion in cash from operations and securing $5.4 billion in free cash flow over the twelve-month period.

Backed by its steady cash generation, Medtronic’s board approved an increase in its quarterly cash dividend to $0.72 per share.

The hike marks the company's 49th consecutive annual dividend increase, placing the manufacturer within a rare class of long-term dividend growth stocks and emphasizing management's ongoing commitment to total shareholder returns.

Looking forward, Medtronic provided an encouraging financial outlook for fiscal year 2027, indicating that structural demand in the medical technology market remains resilient.

The company forecasts full-year organic revenue growth to land between 6.75% and 7.25%.

Additionally, Medtronic expects full-year non-GAAP adjusted earnings per share to range between $5.90 and $6, pointing toward projected efficiency improvements and pipeline launches to counter persistent global inflationary pressures.